Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network

CY Cheah, A George, E Gine, A Chiappella, HC Kluin-Nelemans, W Jurczak, K Krawczyk, H Mocikova, P Klener, D Salek, J Walewski, M Szymczyk, L Smolej, RL Auer, DS Ritchie, L Arcaini, ME Williams, M Dreyling, JF Seymour, Mantle Cell Lymphoma Network European

. 2013 ; 24 (8) : 2119-2123.

Language English Country Great Britain

Grant support
NT13072 MZ0 CEP Register
NT13201 MZ0 CEP Register

BACKGROUND: Central nervous system (CNS) involvement in mantle cell lymphoma (MCL) is uncommon, and the manifestations and natural history are not well described. PATIENTS AND METHODS: We present the data on 57 patients with MCL who developed CNS involvement, from a database of 1396 consecutively treated patients at 14 institutions. RESULTS: The crude incidence of CNS involvement was 4.1%, with 0.9% having CNS involvement at diagnosis. Blastoid histology, B-symptoms, elevated lactate dehydrogenase, Eastern Cooperative Group performance status >=2 and a high Mantle Cell Lymphoma International Prognostic Index score were enriched in the cohort with CNS involvement, and the presence of >=1 of these features defined a high-risk subset (an actuarial risk of CNS involvement 15% at 5 years) in a single-institution subset. The median time to CNS relapse was 15.2 months, and the median survival from time of CNS diagnosis was 3.7 months. The white blood cell count at diagnosis <10.9 x 109/l, treatment of CNS involvement with high-dose anti-metabolites, consolidation with stem cell transplant and achievement of complete response were all associated with improved survival. CONCLUSIONS: In MCL, CNS involvement is uncommon, although some features may predict risk. Once manifest outlook is poor; however, some patients who receive intensive therapy survive longer than 12 months.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19036559
003      
CZ-PrNML
005      
20191113143512.0
007      
ta
008      
191011s2013 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/annonc/mdt139 $2 doi
035    __
$a (PubMed)23616279
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Cheah CY $u Cheah, C Y. Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia.
245    10
$a Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network / $c CY Cheah, A George, E Gine, A Chiappella, HC Kluin-Nelemans, W Jurczak, K Krawczyk, H Mocikova, P Klener, D Salek, J Walewski, M Szymczyk, L Smolej, RL Auer, DS Ritchie, L Arcaini, ME Williams, M Dreyling, JF Seymour, Mantle Cell Lymphoma Network European
520    9_
$a BACKGROUND: Central nervous system (CNS) involvement in mantle cell lymphoma (MCL) is uncommon, and the manifestations and natural history are not well described. PATIENTS AND METHODS: We present the data on 57 patients with MCL who developed CNS involvement, from a database of 1396 consecutively treated patients at 14 institutions. RESULTS: The crude incidence of CNS involvement was 4.1%, with 0.9% having CNS involvement at diagnosis. Blastoid histology, B-symptoms, elevated lactate dehydrogenase, Eastern Cooperative Group performance status >=2 and a high Mantle Cell Lymphoma International Prognostic Index score were enriched in the cohort with CNS involvement, and the presence of >=1 of these features defined a high-risk subset (an actuarial risk of CNS involvement 15% at 5 years) in a single-institution subset. The median time to CNS relapse was 15.2 months, and the median survival from time of CNS diagnosis was 3.7 months. The white blood cell count at diagnosis <10.9 x 109/l, treatment of CNS involvement with high-dose anti-metabolites, consolidation with stem cell transplant and achievement of complete response were all associated with improved survival. CONCLUSIONS: In MCL, CNS involvement is uncommon, although some features may predict risk. Once manifest outlook is poor; however, some patients who receive intensive therapy survive longer than 12 months.
590    __
$a bohemika - dle Pubmed
650    02
$a dospělí $7 D000328
650    02
$a senioři $7 D000368
650    02
$a senioři nad 80 let $7 D000369
650    02
$a protinádorové antimetabolity $x terapeutické užití $7 D000964
650    12
$a centrální nervový systém $x patologie $7 D002490
650    02
$a nádory centrálního nervového systému $x farmakoterapie $x prevence a kontrola $x sekundární $7 D016543
650    02
$a ženské pohlaví $7 D005260
650    02
$a lidé $7 D006801
650    02
$a počet leukocytů $7 D007958
650    12
$a lymfom z plášťových buněk $x farmakoterapie $7 D020522
650    02
$a mužské pohlaví $7 D008297
650    02
$a lidé středního věku $7 D008875
650    02
$a retrospektivní studie $7 D012189
650    02
$a riziko $7 D012306
650    02
$a přežití $7 D013534
650    02
$a výsledek terapie $7 D016896
651    _2
$a Evropa $7 D005060
700    1_
$a George A
700    1_
$a Gine E
700    1_
$a Chiappella A
700    1_
$a Kluin-Nelemans HC
700    1_
$a Jurczak W
700    1_
$a Krawczyk K
700    1_
$a Móciková, Heidi, $d 1964- $7 mzk2009517509
700    1_
$a Klener P
700    1_
$a Šálek, David $7 xx0211647
700    1_
$a Walewski J
700    1_
$a Szymczyk M
700    1_
$a Smolej, Lukáš $7 xx0101489
700    1_
$a Auer RL
700    1_
$a Ritchie DS
700    1_
$a Arcaini L
700    1_
$a Williams ME
700    1_
$a Dreyling M
700    1_
$a Seymour JF
700    1_
$a European Mantle Cell Lymphoma Network
773    0_
$t Annals of Oncology $g Roč. 24, č. 8 (2013), s. 2119-2123 $p Ann Oncol $x 0923-7534 $w MED00000432
773    0_
$p Ann Oncol $g 24(8):2119-23, 2013 Aug
910    __
$a ABA008 $b sig $y 4 $z 0
990    __
$a 20191011130414 $b ABA008
991    __
$a 20191113143749 $b ABA008
999    __
$a ok $b bmc $g 1453867 $s 1075125
BAS    __
$a 3
BMC    __
$a 2013 $b 24 $c 8 $d 2119-2123 $x MED00000432 $i 0923-7534 $m Annals of oncology
GRA    __
$a NT13072 $p MZ0
GRA    __
$a NT13201 $p MZ0
LZP    __
$a NLK 2019/lp

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...